+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Foam dressing with epidermal growth factor for severe radiation dermatitis in head and neck cancer patients

Foam dressing with epidermal growth factor for severe radiation dermatitis in head and neck cancer patients

International Wound Journal 13(3): 390-393

This study was conducted to evaluate the effects of foam dressing with human recombinant human epidermal growth factor (rhEGF) on the healing process in head and neck cancer patients who experience radiation-induced dermatitis (RID). Seven patients, including three with oropharyngeal, two with nasopharyngeal and one each with hypopharyngeal and laryngeal carcinoma, who underwent radiotherapy (RT) for head and neck cancer at the Asan Medical Center from March to December 2008 were prospectively included in this study. Patients who showed severe RID (more than wet desquamation) on the supraclavicular fossa or neck areas were treated by wound cleaning and debridement of granulation tissue, followed by daily rhEGF spray and foam dressing. Median time to stop exudates and reepithelialisation was 4 days. Within 14 days (median 8 days), all patients showed complete healing of RID and no longer required dressings. This new method of treatment with dressing containing rhEGF may have the potential to accelerate the healing process in patients with RID. A case-control study is needed to confirm this finding.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053270624

Download citation: RISBibTeXText

PMID: 24947011

DOI: 10.1111/iwj.12317

Related references

Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies. European Journal of Cancer Care 18(6): 636-641, 2010

Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab. American Journal of Clinical Oncology 32(5): 472-476, 2013

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. Journal of Clinical Oncology 19(13): 3234-3243, 2001

Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 69(2 Suppl): S25-S27, 2007

Salivary epidermal growth factor levels decrease in patients receiving radiation therapy to the head and neck. Oral Surgery Oral Medicine Oral Pathology Oral Radiology & Endodontics 89(6): 710-716, June, 2000

Decreased survival in patients with head and neck cancer who demonstrate elevated expression of transforming growth factor alpha and epidermal growth factor receptor. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 198, 1996

Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncology 41(1): 70-76, 2004

Management of severe bio-radiation dermatitis induced by radiotherapy and cetuximab in patients with head and neck cancer: emphasizing the role of calcium alginate dressings. Supportive Care in Cancer 2018, 2018

Phase 2 study of silver leaf dressing for treatment of radiation-induced dermatitis in patients receiving radiotherapy to the head and neck. Journal of Otolaryngology - Head & Neck Surgery 37(1): 124-129, 2008

A novel fully human monoclonal antibody against epidermal growth factor receptor (EGFR). First clinical and FDG-PET imaging results from a phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology 23(16_suppl): 5530-5530, 2016

Epidermal growth factor receptor inhibitors and radiotherapy for patients with cancer of the head and neck. Current Oncology Reports 9(2): 127-126, 2007

High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. RadioTherapy and Oncology 90(2): 166-171, 2008

Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients. Oral Oncology 43(7): 713-719, 2006

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clinical Cancer Research 7(5): 1204-1213, 2001

Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture. Clinical Cancer Research 18(5): 1313-1322, 2012